OncoZenge AB (publ) (STO:ONCOZ)
Sweden · Delayed Price · Currency is SEK 3.600
-0.050 (-1.37%)
Oct 14, 2026, 5:29 PM CET
OncoZenge AB Earnings Call Transcripts
Fiscal Year 2026
-
Oral mucositis remains a major unmet need for cancer patients, with current treatments often inadequate. A new bupivacaine lozenge is in phase III trials across Europe, supported by strong partnerships and recent financing, with global expansion and additional indications under consideration.